SRC and breast carcinoma: The c-Src, PI3K, ERK, and cyclin D pathways, in particular, play pivotal roles in enabling breast cancer cells to bypass the growth-inhibitory effects of tamoxifen, highlighting the necessity for novel therapeutic strategies.